Literature DB >> 24682418

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.

Eric Lévesque1, Isabelle Laverdière2, Etienne Audet-Walsh2, Patrick Caron2, Mélanie Rouleau2, Yves Fradet2, Louis Lacombe2, Chantal Guillemette3.   

Abstract

PURPOSE: Reliable biomarkers that predict prostate cancer outcomes are urgently needed to improve and personalize treatment approaches. With this goal in mind, we individually and collectively appraised common genetic polymorphisms related to estradiol metabolic pathways to find prostate cancer prognostic markers.
METHODS: The genetic profiles of 526 men with organ-confined prostate cancer were examined to find common genetic polymorphisms related to estradiol metabolic pathways and these findings were replicated in a cohort of 213 men with more advanced disease (follow-up time for both cohorts, >7.4 years). Specifically, we examined 71 single-nucleotide polymorphisms (SNP) in SULT2A1, SULT2B1, CYP1B1, COMT, CYP3A4, CYP3A5, CYP3A43, NQO1, and NQO2 and assessed the impact of the SNPs alone and in combination on prostate cancer progression and on circulating hormone levels.
RESULTS: According to a multivariate analysis, CYP1B1 (rs1800440), COMT (rs16982844), and SULT2B1 (rs12460535, rs2665582, rs10426628) were significantly associated with prostate cancer progression and hormone levels. Remarkably, by combining the SNP information with previously identified HSD17B2 markers, the patients could be stratified into four distinct prognostic subgroups. The most prominent association was observed for the eight-marker combination [CYP1B1 (rs1800440), SULT2B1 (rs12460535, rs2665582, and rs10426628), and HSD17B2 (rs4243229, rs1364287, rs2955162, and rs1119933)].
CONCLUSION: This study identified specific germline variations in estradiol metabolism-related pathways, namely CYP1B1, SULT2B1, and HSD17B2, as novel prognostic markers that are cumulatively associated with increased risk of prostate cancer progression. This panel of markers warrants additional investigation and validation to help stratify patients according to their risk of progression. Clin Cancer Res; 20(11); 2971-83. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24682418     DOI： 10.1158/1078-0432.CCR-13-2567

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Authors:  Jean-Nicolas Cornu; Etienne Audet-Walsh; Sarah Drouin; Pierre Bigot; Antoine Valeri; Georges Fournier; Abdel-Rahmène Azzouzi; Morgan Roupret; Luc Cormier; Stephen Chanock; Chantal Guillemette; Olivier Cussenot; Eric Lévesque; Géraldine Cancel-Tassin
Journal:  World J Urol       Date:  2016-06-08       Impact factor: 4.226

2.  Effect of SULT2B1 genetic polymorphisms on the sulfation of dehydroepiandrosterone and pregnenolone by SULT2B1b allozymes.

Authors:  Fatemah A Alherz; Amal A El Daibani; Maryam S Abunnaja; Ahsan F Bairam; Mohammed I Rasool; Yoichi Sakakibara; Masahito Suiko; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  Mol Cell Endocrinol       Date:  2019-08-07       Impact factor: 4.102

3.  On the role of genetic polymorphisms in the sulfation of cholesterol by human cytosolic sulphotransferase SULT2B1b.

Authors:  Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Ahsan F Bairam; Mohammed I Rasool; Katsuhisa Kurogi; Yoichi Sakakibara; Masahito Suiko; Ming-Cheh Liu
Journal:  J Biochem       Date:  2018-09-01       Impact factor: 3.387

4.  Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Authors:  Kathleen E Houlahan; Yu-Jia Shiah; Alexander Gusev; Jiapei Yuan; Musaddeque Ahmed; Anamay Shetty; Susmita G Ramanand; Cindy Q Yao; Connor Bell; Edward O'Connor; Vincent Huang; Michael Fraser; Lawrence E Heisler; Julie Livingstone; Takafumi N Yamaguchi; Alexandre Rouette; Adrien Foucal; Shadrielle Melijah G Espiritu; Ankit Sinha; Michelle Sam; Lee Timms; Jeremy Johns; Ada Wong; Alex Murison; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Mathieu Lupien; Yves Fradet; Bernard Têtu; John D McPherson; Bogdan Pasaniuc; Thomas Kislinger; Melvin L K Chua; Mark M Pomerantz; Theodorus van der Kwast; Matthew L Freedman; Ram S Mani; Housheng H He; Robert G Bristow; Paul C Boutros
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

5.  Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression.

Authors:  Jean-Philippe Emond; Louis Lacombe; Patrick Caron; Véronique Turcotte; David Simonyan; Armen Aprikian; Fred Saad; Michel Carmel; Simone Chevalier; Chantal Guillemette; Eric Lévesque
Journal:  Br J Cancer       Date:  2021-04-07       Impact factor: 7.640

6.  Overexpression of SULT2B1b is an independent prognostic indicator and promotes cell growth and invasion in colorectal carcinoma.

Authors:  Liang Hu; Guang-Zhen Yang; Yu Zhang; Dan Feng; Yan-Xia Zhai; Hui Gong; Chen-Ye Qi; Hao Fu; Ming-Ming Ye; Qing-Ping Cai; Chun-Fang Gao
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 7.  The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.

Authors:  Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2016-02-18       Impact factor: 5.810

8.  Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.

Authors:  Alba Mota; Juan Carlos Triviño; Alejandro Rojo-Sebastian; Ángel Martínez-Ramírez; Luis Chiva; Antonio González-Martín; Juan F Garcia; Pablo Garcia-Sanz; Gema Moreno-Bueno
Journal:  BMC Cancer       Date:  2015-11-30       Impact factor: 4.430

9.  MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

Authors:  Jun-Long Wu; Shu-Xian Zhou; Rui Zhao; Xuan Zhang; Kun Chang; Cheng-Yuan Gu; Hua-Lei Gan; Bo Dai; Yao Zhu; Hai-Liang Zhang; Guo-Hai Shi; Yuan-Yuan Qu; Jian-Yuan Zhao; Ding-Wei Ye
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

Review 10.  Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer.

Authors:  Konrad Sopyllo; Andrew M Erickson; Tuomas Mirtti
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.